Pakistan's pharmaceutical sector experienced significant upheaval following price deregulation policies, resulting in the departure of five major pharmaceutical companies. According to the Pakistan Young Pharmacists Association, some firms opted for joint venture arrangements that ultimately proved incompatible with continued local operations. The Drug Regulatory Authority of Pakistan provided insight into these structural challenges, highlighting how regulatory changes can reshape market dynamics and influence multinational pharmaceutical strategies in emerging markets.

Summary auto-generated by AI from the original publisher's content. Editorial standards.